Resultats globals: 2 registres trobats en 0.02 segons.
Articles, 2 registres trobats
Articles 2 registres trobats  
1.
11 p, 693.2 KB ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation / Malcikova, J. (Brno, Czech Republic) ; Tausch, E. (Ulm, Germany) ; Rossi, D. (Bellinzona, Switzerland) ; Sutton, L. A. (Stockholm, Sweden) ; Soussi, T. (Stockholm, Sweden) ; Zenz, T. (Zürich, Switzerland) ; Kater, A. P. (Amsterdam, The Netherlands) ; Niemann, C. U. (Copenhagen, Denmark) ; González De Castro, David (Belfast, UK) ; Davi, F. (Paris, France) ; Gonzalez Diaz, M. (Salamanca, Spain) ; Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ; Gaidano, G. (Novara, Italy) ; Stamatopoulos, K. (Thessaloniki, Greece) ; Rosenquist, R. (Stockholm, Sweden) ; Stilgenbauer, S. (Ulm, Germany) ; Ghia, P. (Milan, Italy) ; Pospisilova, S. (Brno, Czech Republic) ; Universitat Autònoma de Barcelona
In chronic lymphocytic leukemia (CLL), TP53 gene defects, due to deletion of the 17p13 locus and/or mutation(s) within the TP53 gene, are associated with resistance to chemoimmunotherapy and a particularly dismal clinical outcome. [...]
2018 - 10.1038/s41375-017-0007-7
Leukemia, Vol. 32 (february 2018) , p. 1070-1080  
2.
6 p, 225.1 KB Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer : results of the EXPERT-C trial / Sclafani, F. (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Chau, I. (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Cunningham, D. (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Peckitt, C. (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Lampis, A. (The Institute of Cancer Research. Division of Molecular Pathology (UK)) ; Hahne, J. C. (The Institute of Cancer Research. Division of Molecular Pathology (UK)) ; Braconi, C. (The Institute of Cancer Research. Division of Cancer Therapeutics (UK)) ; Taberneroo, J (Hospital Universitari Vall d'Hebron) ; Glimelius, B. (University of Uppsala. Department of Immunology, Genetics and Pathology (Sweden)) ; Cervantes, A. (Universidad de Valencia. Departamento de Hematología y Oncología Médica) ; Begum, R. (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Gonzalez De Castro, David (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Hulkki Wilson, S. (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Eltahir, Z. (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Wotherspoon, A. (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Tait, D. (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Brown, G. (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Oates, J. (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Valeri, N. (The Institute of Cancer Research. Division of Molecular Pathology (UK)) ; Universitat Autònoma de Barcelona
Lethal-7 (let-7) is a tumour suppressor miRNA which acts by down-regulating several oncogenes including KRAS. A single-nucleotide polymorphism (rs61764370, T > G base substitution) in the let-7 complementary site 6 (LCS-6) of KRAS mRNA has been shown to predict prognosis in early-stage colorectal cancer (CRC) and benefit from anti-epidermal growth factor receptor monoclonal antibodies in metastatic CRC. [...]
2015 - 10.1093/annonc/mdv285
Annals of oncology, Vol. 26, Issue 9 (September 2015) , p. 1936-1941  

Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.